

Stanley R Hamilton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6382092/publications.pdf>

Version: 2024-02-01

34
papers

2,338
citations

394421

19
h-index

414414

32
g-index

34
all docs

34
docs citations

34
times ranked

4501
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561. | 1.6 | 26 |
| 2 | Phase II Study of Taselisib in <i>PIK3CA</i> -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424. | 3.0 | 9 |
| 3 | Phase I/II first-in-human CAR Tâ€“targeting MUC1 transmembrane cleavage product (MUC1*) in patients with metastatic breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1130-TPS1130. | 1.6 | 3 |
| 4 | Phase II study of vismodegib in patients with <i>SMO</i> or <i>PTCH1</i> mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3010-3010. | 1.6 | 1 |
| 5 | Comparison of AYA versus non-AYA ovarian cancer genomic landscape in NCI-MATCH trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, e17617-e17617. | 1.6 | 0 |
| 6 | Effect of Capivasertib in Patients With an <i>AKT1 E17K</i> -Mutated Tumor. <i>JAMA Oncology</i> , 2021, 7, 271. | 7.1 | 49 |
| 7 | Proliferation, apoptosis and their regulatory protein expression in colorectal adenomas and serrated lesions. <i>PLoS ONE</i> , 2021, 16, e0258878. | 2.5 | 1 |
| 8 | The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1021-1029. | 6.3 | 138 |
| 9 | Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). <i>Journal of Clinical Oncology</i> , 2020, 38, 3883-3894. | 1.6 | 168 |
| 10 | State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trialsâ€”A Multidisciplinary Approach. <i>Journal of Clinical Oncology</i> , 2020, 38, 1633-1640. | 1.6 | 12 |
| 11 | ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectalâ€”Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 757-770. | 27.6 | 218 |
| 12 | Characterizing the Killer Colorectal Carcinomas. <i>Cancer Cell</i> , 2018, 33, 7-9. | 16.8 | 14 |
| 13 | Validation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial. <i>Clinical Cancer Research</i> , 2018, 24, 521-531. | 7.0 | 64 |
| 14 | Status of Testing for High-Level Microsatellite Instability/Deficient Mismatch Repair in Colorectal Carcinoma. <i>JAMA Oncology</i> , 2018, 4, e173574. | 7.1 | 2 |
| 15 | Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for <i>PIK3CA</i> -mutated tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 101-101. | 1.6 | 29 |
| 16 | Molecular Biomarkers for the Evaluation of Colorectal Cancer. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 187-225. | 2.8 | 108 |
| 17 | Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 313-327. | 2.8 | 115 |
| 18 | <i>MIP</i> haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer. <i>Journal of Pathology</i> , 2017, 241, 67-79. | 4.5 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | <i>FBXW7</i> missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017, 8, 39268-39279. | 1.8 | 69 |
| 20 | Clinical and Molecular Characteristics of Post-Colonoscopy Colorectal Cancer: A Population-based Study. <i>Gastroenterology</i> , 2016, 151, 870-878.e3. | 1.3 | 53 |
| 21 | Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. <i>British Journal of Cancer</i> , 2016, 114, 1352-1361. | 6.4 | 81 |
| 22 | Increased Risk of Colorectal Cancer Development Among Patients With Serrated Polyps. <i>Gastroenterology</i> , 2016, 150, 895-902.e5. | 1.3 | 184 |
| 23 | The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. <i>Gut</i> , 2016, 65, 977-989. | 12.1 | 111 |
| 24 | Examining plasma microRNA markers for colorectal cancer at different stages. <i>Oncotarget</i> , 2016, 7, 11434-11449. | 1.8 | 74 |
| 25 | Regulation of AURKC expression by CpG island methylation in human cancer cells. <i>Tumor Biology</i> , 2015, 36, 8147-8158. | 1.8 | 9 |
| 26 | Assessment of <i>BRAF</i> V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2887-2895. | 4.1 | 38 |
| 27 | Pragmatic issues in biomarker evaluation for targeted therapies in cancer. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 197-212. | 27.6 | 162 |
| 28 | Differential expression of microRNA-320a, -145, and -192 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum. <i>American Journal of Surgery</i> , 2014, 207, 717-722. | 1.8 | 11 |
| 29 | Molecular pathology. <i>Molecular Oncology</i> , 2012, 6, 177-181. | 4.6 | 8 |
| 30 | 2010 Staging System for Colon and Rectal Carcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 1513-1517. | 1.5 | 14 |
| 31 | Targeted therapy of cancer: new roles for pathologists in colorectal cancer. <i>Modern Pathology</i> , 2008, 21, S23-S30. | 5.5 | 55 |
| 32 | Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 18654-18659. | 7.1 | 496 |
| 33 | Expression of p27Kip1 and bcl-2, cigarette smoking, and colorectal cancer risk. <i>Biomarkers</i> , 2000, 5, 225-234. | 1.9 | 3 |
| 34 | Malignant Tumors of the Colon. , 0, , 1669-1716. | | 0 |